Genenews Limited (GEN.TO) 1.30 $GEN.TO
GeneNews Early Stage Cancer Diagnosis, CEO Clip Video
Newsfile Corp - Tue Jul 22, 1:00PM CDT
full story)
GeneNews Raises More Than $7 Million in Non-Brokered Private Placement
GlobeNewswire - Tue Jul 08, 8:24AM CDT
NOT FOR DISTRIBUTION TO UNITED STATES NEWS SERVICES OR DISSEMINATION
GeneNews Limited Announces Proposed Private Placement
GlobeNewswire - Wed Jul 02, 8:57AM CDT
NOT FOR DISTRIBUTION TO UNITED STATES NEWS SERVICES OR DISSEMINATION
IIROC Trade Resumption - GEN
CNW Group - Wed Jul 02, 8:10AM CDT
Trading resumes in:
IIROC Trading Halt - GEN
CNW Group - Wed Jul 02, 7:41AM CDT
The following issues have been halted by IIROC:
GeneNews Reports Full Year and Q4 2013 Financial Results
GlobeNewswire - Tue Mar 04, 5:48PM CST
GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company"
today reported operational and financial results for the three-month and full-year periods ended December 31, 2013. All dollar amounts are expressed in Canadian currency unless otherwise indicated and results are reported in accordance with International Financial Reporting Standards.
GeneNews' Innovative Diagnostic Laboratory J-V Initiates U.S.-Wide Roll Out of ColonSentry(R) and Adds Important New Test to Offering Menu
GlobeNewswire - Tue Jan 21, 7:30AM CST
GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company" today provided a progress update on the commercial operations of its recently formed joint venture, Innovative Diagnostic Laboratory LLP ("IDL", including the full-scale rollout of the ColonSentry(R) test throughout the United States and the addition of EarlyCDT(R)-Lung - a simple blood test that aids physicians in risk assessment and the early detection of lung cancer in high-risk, asymptomatic patients - to IDL's offering.
Zenyatta Ventures Announces Filing of Technical Report
Marketwire - Thu Jan 16, 4:49PM CST
Zenyatta Ventures Ltd. ("Zenyatta" or "Company" (TSX VENTURE: ZEN) reports that further to its news release dated December 2, 2013, it has filed a technical report (the "Technical Report" in respect of the Company's 100%-owned Albany graphite deposit located in northeastern Ontario, Canada.
GeneNews Limited Announces Extension of Term of Related Warrants
GlobeNewswire - Mon Dec 30, 7:00AM CST
GeneNews Limited ("GeneNews" or the "Company" (TSX:GEN) announces, further to its press releases of November 13, December 5, December 12, December 16 and December 19, 2013 the extension of the term of certain related warrants (the "Related Warrants" in connection with a conversion of certain outstanding convertible debentures of the Company (the "Convertible Debentures".
PDL BioPharma IncCorporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 8:03PM CST
Mr. Rory Riggs of 110 East 59th Street, 33rd Floor, Suite 3302, New York, NY, 10022, USA, chairman of the board of directors of GeneNews Limited (TSX: GEN) ("GeneNews" announces that on December 14, 2012, Mr. Riggs completed a subscription for 4,139,400 common shares ("Common Shares" of GeneNews, at a price per Common Share of $0.09 through a previously announced private placement (the "Private Placement" by GeneNews.
GeneNews Limited Announces Conversion of Convertible Debentures Into Common Shares
GlobeNewswire - Thu Dec 19, 9:10AM CST
GeneNews Limited ("GeneNews" or the "Company" (TSX:GEN) announces, further to its press releases of November 13, December 5, December 12 and December 16, 2013, the conversion today of $2,728,942 outstanding convertible debentures of the Company (the "Convertible Debentures" plus accrued interest of $2,046,708 into a total of 10,160,957 common shares of the Company (the "Common Shares". The holders of the Convertible Debentures converted the principal amount of their Convertible Debentures, together with the accrued and unpaid interest thereon, into Common Shares at a price per Common Share of $0.47, which was equal to 90% of the five (5) day volume weighted average price of the Common Shares on the Toronto Stock Exchange for the period ending on December 11, 2013. The issuance of the Common Shares represents a dilution of 30% of the 33,744,883 previously issued and outstanding Common Shares.
GeneNews Limited Announces Shareholder Approval of Conversion Opportunity for Debentureholders
GlobeNewswire - Mon Dec 16, 3:30PM CST
Further to its press releases of November 13, December 5, and December 12, 2013, GeneNews Limited ("GeneNews" or the "Company" (TSX:GEN) announces that, at a special meeting of the Company's shareholders held today, approval of the shareholders was obtained for the issuance of common shares of the Company ("Common Shares" to holders of the outstanding convertible debentures of the Company (the "Convertible Debentures" in connection with a one-time conversion opportunity (the "Conversion Opportunity". Holders of Convertible Debentures may convert the principal amount of their Convertible Debentures, together with accrued and unpaid interest thereon, into Common Shares as of December 18, 2013 at a price per Common Share of $0.47, which is equal to 90% of the five (5) day volume weighted average price of the Common Shares on the Toronto Stock Exchange (the "TSX" for the period ending on December 11, 2013. If all of the outstanding Convertible Debentures participate in the Conversion Opportunity, a total of 11,696,861 Common Shares will be issued, which represents a dilution of 35% of the 33,744,883 currently issued and outstanding Common Shares.
GeneNews Limited Announces Conversion Price of Conversion Opportunity for Debentureholders
GlobeNewswire - Thu Dec 12, 7:45AM CST
GeneNews Limited ("GeneNews" or the "Company" (TSX:GEN) announced today that, further to its press releases of November 13 and December 5, 2013, holders of outstanding convertible debentures of the Company (the "Convertible Debentures" may convert the principal amount of their Convertible Debentures (the "Conversion Opportunity", together with accrued and unpaid interest thereon, into common shares of the Company ("Common Shares" as of December 18, 2013, at a price per Common Share of $0.47, which is equal to 90% of the five (5) day volume weighted average price of the Common Shares on the Toronto Stock Exchange (the "TSX" for the period ending on December 11, 2013. If all of the outstanding Convertible Debentures participate in the Conversion Opportunity, a total of 11,696,861 Common Shares will be issued, which represents a dilution of 35% of the 33,744,883 currently issued and outstanding Common Shares.
GeneNews Announces Strategic Restructuring
GlobeNewswire - Tue Aug 20, 6:00AM CDT
GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company" today announced a strategic restructuring, including senior management changes and staff reductions, designed to further position its recently formed joint venture, Innovative Diagnostic Laboratory LLP ("IDL", to become a leader in molecular diagnostics and personalized medicine, with a primary focus on cancer-related indications.
GeneNews Reports Q2 2013 Financial Results
GlobeNewswire - Fri Aug 09, 3:15PM CDT
GeneNews Limited (TSX:GEN), a company focused on developing and commercializing molecular diagnostic tests for the early detection of diseases and personalized health management, today reported operational and financial results for the three-month and six-month periods ended June 30, 2013.
GeneNews Announces Management and Board Changes
GlobeNewswire - Mon Jul 15, 7:30AM CDT
GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company" today announced a number of Board and management changes designed to better position its recently formed joint venture, Innovative Diagnostic Laboratory LLP ("IDL", to become a leader in molecular diagnostics and personalized medicine, with a primary focus on cancer-related indications.
GeneNews Enters Into Joint Venture to Establish US CLIA Lab
GlobeNewswire - Tue Jul 02, 7:00AM CDT
GeneNews Limited (TSX:GEN) announced today that it has formed a joint venture with two private American companies, Health Diagnostic Laboratory, Inc. ("HDL" and a sales organization with national capabilities, to establish an accredited clinical laboratory called Innovative Diagnostic Laboratory, LLP ("IDL". IDL will initially focus on the development and broader US commercialization of ColonSentry and is expected to be functional and certified under the Clinical Lab Improvement Amendments Act ("CLIA" in the third quarter.
Leslie Auld Appointed to GeneNews Board of Directors
GlobeNewswire - Fri Jun 28, 6:43PM CDT
GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company", a company focused on developing and commercializing blood-based biomarker tests for the early detection of diseases and personalized health management, announced today that its Chief Financial Officer and Treasurer, Leslie Auld, has been appointed to the Company's Board of Directors.
GeneNews to Present at the Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire - Tue May 21, 12:30PM CDT
GeneNews Limited (TSX:GEN) ("GeneNews" announced today that its President and Chief Operating Officer, Gailina J. Liew, will present an update on the Company's business at the 2nd Annual Bloom Burton & Co. Healthcare Investor Conference on Wednesday, May 22, 2013 at 2:30 PM ET. The conference will be held at the Toronto Board of Trade in Toronto, ON.
GeneNews Early Stage Cancer Diagnosis, CEO Clip Video
Newsfile Corp - Tue Jul 22, 1:00PM CDT
full story)
GeneNews Raises More Than $7 Million in Non-Brokered Private Placement
GlobeNewswire - Tue Jul 08, 8:24AM CDT
NOT FOR DISTRIBUTION TO UNITED STATES NEWS SERVICES OR DISSEMINATION
GeneNews Limited Announces Proposed Private Placement
GlobeNewswire - Wed Jul 02, 8:57AM CDT
NOT FOR DISTRIBUTION TO UNITED STATES NEWS SERVICES OR DISSEMINATION
IIROC Trade Resumption - GEN
CNW Group - Wed Jul 02, 8:10AM CDT
Trading resumes in:
IIROC Trading Halt - GEN
CNW Group - Wed Jul 02, 7:41AM CDT
The following issues have been halted by IIROC:
GeneNews Reports Full Year and Q4 2013 Financial Results
GlobeNewswire - Tue Mar 04, 5:48PM CST
GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company"
today reported operational and financial results for the three-month and full-year periods ended December 31, 2013. All dollar amounts are expressed in Canadian currency unless otherwise indicated and results are reported in accordance with International Financial Reporting Standards. GeneNews' Innovative Diagnostic Laboratory J-V Initiates U.S.-Wide Roll Out of ColonSentry(R) and Adds Important New Test to Offering Menu
GlobeNewswire - Tue Jan 21, 7:30AM CST
GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company"
today provided a progress update on the commercial operations of its recently formed joint venture, Innovative Diagnostic Laboratory LLP ("IDL", including the full-scale rollout of the ColonSentry(R) test throughout the United States and the addition of EarlyCDT(R)-Lung - a simple blood test that aids physicians in risk assessment and the early detection of lung cancer in high-risk, asymptomatic patients - to IDL's offering. Zenyatta Ventures Announces Filing of Technical Report
Marketwire - Thu Jan 16, 4:49PM CST
Zenyatta Ventures Ltd. ("Zenyatta" or "Company"
(TSX VENTURE: ZEN) reports that further to its news release dated December 2, 2013, it has filed a technical report (the "Technical Report" in respect of the Company's 100%-owned Albany graphite deposit located in northeastern Ontario, Canada. GeneNews Limited Announces Extension of Term of Related Warrants
GlobeNewswire - Mon Dec 30, 7:00AM CST
GeneNews Limited ("GeneNews" or the "Company"
(TSX:GEN) announces, further to its press releases of November 13, December 5, December 12, December 16 and December 19, 2013 the extension of the term of certain related warrants (the "Related Warrants" in connection with a conversion of certain outstanding convertible debentures of the Company (the "Convertible Debentures". PDL BioPharma IncCorporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 8:03PM CST
Mr. Rory Riggs of 110 East 59th Street, 33rd Floor, Suite 3302, New York, NY, 10022, USA, chairman of the board of directors of GeneNews Limited (TSX: GEN) ("GeneNews"
announces that on December 14, 2012, Mr. Riggs completed a subscription for 4,139,400 common shares ("Common Shares" of GeneNews, at a price per Common Share of $0.09 through a previously announced private placement (the "Private Placement" by GeneNews. GeneNews Limited Announces Conversion of Convertible Debentures Into Common Shares
GlobeNewswire - Thu Dec 19, 9:10AM CST
GeneNews Limited ("GeneNews" or the "Company"
(TSX:GEN) announces, further to its press releases of November 13, December 5, December 12 and December 16, 2013, the conversion today of $2,728,942 outstanding convertible debentures of the Company (the "Convertible Debentures" plus accrued interest of $2,046,708 into a total of 10,160,957 common shares of the Company (the "Common Shares". The holders of the Convertible Debentures converted the principal amount of their Convertible Debentures, together with the accrued and unpaid interest thereon, into Common Shares at a price per Common Share of $0.47, which was equal to 90% of the five (5) day volume weighted average price of the Common Shares on the Toronto Stock Exchange for the period ending on December 11, 2013. The issuance of the Common Shares represents a dilution of 30% of the 33,744,883 previously issued and outstanding Common Shares. GeneNews Limited Announces Shareholder Approval of Conversion Opportunity for Debentureholders
GlobeNewswire - Mon Dec 16, 3:30PM CST
Further to its press releases of November 13, December 5, and December 12, 2013, GeneNews Limited ("GeneNews" or the "Company"
(TSX:GEN) announces that, at a special meeting of the Company's shareholders held today, approval of the shareholders was obtained for the issuance of common shares of the Company ("Common Shares" to holders of the outstanding convertible debentures of the Company (the "Convertible Debentures" in connection with a one-time conversion opportunity (the "Conversion Opportunity". Holders of Convertible Debentures may convert the principal amount of their Convertible Debentures, together with accrued and unpaid interest thereon, into Common Shares as of December 18, 2013 at a price per Common Share of $0.47, which is equal to 90% of the five (5) day volume weighted average price of the Common Shares on the Toronto Stock Exchange (the "TSX" for the period ending on December 11, 2013. If all of the outstanding Convertible Debentures participate in the Conversion Opportunity, a total of 11,696,861 Common Shares will be issued, which represents a dilution of 35% of the 33,744,883 currently issued and outstanding Common Shares. GeneNews Limited Announces Conversion Price of Conversion Opportunity for Debentureholders
GlobeNewswire - Thu Dec 12, 7:45AM CST
GeneNews Limited ("GeneNews" or the "Company"
(TSX:GEN) announced today that, further to its press releases of November 13 and December 5, 2013, holders of outstanding convertible debentures of the Company (the "Convertible Debentures" may convert the principal amount of their Convertible Debentures (the "Conversion Opportunity", together with accrued and unpaid interest thereon, into common shares of the Company ("Common Shares" as of December 18, 2013, at a price per Common Share of $0.47, which is equal to 90% of the five (5) day volume weighted average price of the Common Shares on the Toronto Stock Exchange (the "TSX" for the period ending on December 11, 2013. If all of the outstanding Convertible Debentures participate in the Conversion Opportunity, a total of 11,696,861 Common Shares will be issued, which represents a dilution of 35% of the 33,744,883 currently issued and outstanding Common Shares. GeneNews Announces Strategic Restructuring
GlobeNewswire - Tue Aug 20, 6:00AM CDT
GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company"
today announced a strategic restructuring, including senior management changes and staff reductions, designed to further position its recently formed joint venture, Innovative Diagnostic Laboratory LLP ("IDL", to become a leader in molecular diagnostics and personalized medicine, with a primary focus on cancer-related indications. GeneNews Reports Q2 2013 Financial Results
GlobeNewswire - Fri Aug 09, 3:15PM CDT
GeneNews Limited (TSX:GEN), a company focused on developing and commercializing molecular diagnostic tests for the early detection of diseases and personalized health management, today reported operational and financial results for the three-month and six-month periods ended June 30, 2013.
GeneNews Announces Management and Board Changes
GlobeNewswire - Mon Jul 15, 7:30AM CDT
GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company"
today announced a number of Board and management changes designed to better position its recently formed joint venture, Innovative Diagnostic Laboratory LLP ("IDL", to become a leader in molecular diagnostics and personalized medicine, with a primary focus on cancer-related indications. GeneNews Enters Into Joint Venture to Establish US CLIA Lab
GlobeNewswire - Tue Jul 02, 7:00AM CDT
GeneNews Limited (TSX:GEN) announced today that it has formed a joint venture with two private American companies, Health Diagnostic Laboratory, Inc. ("HDL"
and a sales organization with national capabilities, to establish an accredited clinical laboratory called Innovative Diagnostic Laboratory, LLP ("IDL". IDL will initially focus on the development and broader US commercialization of ColonSentry and is expected to be functional and certified under the Clinical Lab Improvement Amendments Act ("CLIA" in the third quarter. Leslie Auld Appointed to GeneNews Board of Directors
GlobeNewswire - Fri Jun 28, 6:43PM CDT
GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company"
, a company focused on developing and commercializing blood-based biomarker tests for the early detection of diseases and personalized health management, announced today that its Chief Financial Officer and Treasurer, Leslie Auld, has been appointed to the Company's Board of Directors. GeneNews to Present at the Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire - Tue May 21, 12:30PM CDT
GeneNews Limited (TSX:GEN) ("GeneNews"
announced today that its President and Chief Operating Officer, Gailina J. Liew, will present an update on the Company's business at the 2nd Annual Bloom Burton & Co. Healthcare Investor Conference on Wednesday, May 22, 2013 at 2:30 PM ET. The conference will be held at the Toronto Board of Trade in Toronto, ON. 
